JP2010509224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509224A5 JP2010509224A5 JP2009535353A JP2009535353A JP2010509224A5 JP 2010509224 A5 JP2010509224 A5 JP 2010509224A5 JP 2009535353 A JP2009535353 A JP 2009535353A JP 2009535353 A JP2009535353 A JP 2009535353A JP 2010509224 A5 JP2010509224 A5 JP 2010509224A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- trifluoromethyl
- cyclohexyl
- cis
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- -1 hydroxy, amino Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- AYGLTQXKFKWBDG-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-[4-(trifluoromethyl)cyclohexyl]purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2C1CCC(C(F)(F)F)CC1 AYGLTQXKFKWBDG-UHFFFAOYSA-N 0.000 claims 1
- FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- HIIIHZSJVUWOSN-BETUJISGSA-N C1=CC(F)=CC=C1N1C(=O)C(N=CN2C3CC3)=C2N=C1[C@@H]1CC[C@H](C(F)(F)F)CC1 Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CN2C3CC3)=C2N=C1[C@@H]1CC[C@H](C(F)(F)F)CC1 HIIIHZSJVUWOSN-BETUJISGSA-N 0.000 claims 1
- UJXJMPFPQYDYSG-BETUJISGSA-N C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1[C@@H]1CC[C@H](C(F)(F)F)CC1 Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1[C@@H]1CC[C@H](C(F)(F)F)CC1 UJXJMPFPQYDYSG-BETUJISGSA-N 0.000 claims 1
- LLLYTZXKCBSTBG-BETUJISGSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C(N(C1=O)C=2C=CC(Cl)=CC=2)=NC2=C1N=CN2C1CC1 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C(N(C1=O)C=2C=CC(Cl)=CC=2)=NC2=C1N=CN2C1CC1 LLLYTZXKCBSTBG-BETUJISGSA-N 0.000 claims 1
- JTYYMSBUNAYGME-PHIMTYICSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C(N(C1=O)C=2C=CC(Cl)=CC=2)=NC2=C1N=CS2 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C(N(C1=O)C=2C=CC(Cl)=CC=2)=NC2=C1N=CS2 JTYYMSBUNAYGME-PHIMTYICSA-N 0.000 claims 1
- UHJFWMRDGROPRO-GASCZTMLSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(C#N)C=C1 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(C#N)C=C1 UHJFWMRDGROPRO-GASCZTMLSA-N 0.000 claims 1
- YEAKNWWDTSYOKL-BETUJISGSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(C#N)N=C1 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(C#N)N=C1 YEAKNWWDTSYOKL-BETUJISGSA-N 0.000 claims 1
- DEASAZHBQIHIFA-BETUJISGSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(Cl)C=C1 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(Cl)C=C1 DEASAZHBQIHIFA-BETUJISGSA-N 0.000 claims 1
- SHBDCXWCHZVXDX-TXEJJXNPSA-N C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(Cl)N=C1 Chemical compound C1C[C@H](C(F)(F)F)CC[C@@H]1C1=NC2=CC=CN=C2C(=O)N1C1=CC=C(Cl)N=C1 SHBDCXWCHZVXDX-TXEJJXNPSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- RSFQFNKVYBJDJW-BETUJISGSA-N CC1=CSC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CC1=CSC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 RSFQFNKVYBJDJW-BETUJISGSA-N 0.000 claims 1
- FKIMRZFNOVMUGI-BETUJISGSA-N CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 FKIMRZFNOVMUGI-BETUJISGSA-N 0.000 claims 1
- MPHQVVLTRVIGBI-TXEJJXNPSA-N CC1=CSC(C(N2C=3C=NC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CC1=CSC(C(N2C=3C=NC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 MPHQVVLTRVIGBI-TXEJJXNPSA-N 0.000 claims 1
- VDXQQWSQJUJRFP-BETUJISGSA-N CCN1C(NC)=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C(NC)=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 VDXQQWSQJUJRFP-BETUJISGSA-N 0.000 claims 1
- IMWJTAIUBAWDAN-GASCZTMLSA-N CCN1C=NC(C(N2C=3C=CC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C=NC(C(N2C=3C=CC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 IMWJTAIUBAWDAN-GASCZTMLSA-N 0.000 claims 1
- GTUVUBQNXGRIJF-IYBDPMFKSA-N CCN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@@H]1CC[C@H](C(C)C)CC1 Chemical compound CCN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@@H]1CC[C@H](C(C)C)CC1 GTUVUBQNXGRIJF-IYBDPMFKSA-N 0.000 claims 1
- RQNZRTBPZIKUBT-BETUJISGSA-N CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 RQNZRTBPZIKUBT-BETUJISGSA-N 0.000 claims 1
- SKTMBCJPHMHHPQ-BETUJISGSA-N CCN1C=NC(C(N2C=3C=NC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C=NC(C(N2C=3C=NC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 SKTMBCJPHMHHPQ-BETUJISGSA-N 0.000 claims 1
- WLSCVKTXJCQLLZ-OKILXGFUSA-N CCN1C=NC(C(N2C=3C=NC(C)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C=NC(C(N2C=3C=NC(C)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 WLSCVKTXJCQLLZ-OKILXGFUSA-N 0.000 claims 1
- BVCCTFZDEIJBMF-TXEJJXNPSA-N CCN1C=NC(C(N2C=3C=NC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CCN1C=NC(C(N2C=3C=NC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 BVCCTFZDEIJBMF-TXEJJXNPSA-N 0.000 claims 1
- VMRNQWZHONBIMR-OKILXGFUSA-N CN1C=NC(C(N2C=3C=CC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CN1C=NC(C(N2C=3C=CC(=CC=3)C#N)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 VMRNQWZHONBIMR-OKILXGFUSA-N 0.000 claims 1
- JKBUTUUHZFRCAS-TXEJJXNPSA-N CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2[C@H]1CC[C@@H](C(F)(F)F)CC1 JKBUTUUHZFRCAS-TXEJJXNPSA-N 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010027304 Menopausal symptoms Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 239000006002 Pepper Substances 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 235000016761 Piper aduncum Nutrition 0.000 claims 1
- 235000017804 Piper guineense Nutrition 0.000 claims 1
- 244000203593 Piper nigrum Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 102000011040 TRPV Cation Channels Human genes 0.000 claims 1
- 108010062740 TRPV Cation Channels Proteins 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000809 air pollutant Substances 0.000 claims 1
- 231100001243 air pollutant Toxicity 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 206010041232 sneezing Diseases 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 231100000133 toxic exposure Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86446006P | 2006-11-06 | 2006-11-06 | |
| PCT/US2007/023318 WO2008066664A2 (en) | 2006-11-06 | 2007-11-05 | Cis-cyclohexyl substituted pyrimidinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509224A JP2010509224A (ja) | 2010-03-25 |
| JP2010509224A5 true JP2010509224A5 (enExample) | 2010-12-24 |
Family
ID=39468435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535353A Pending JP2010509224A (ja) | 2006-11-06 | 2007-11-05 | ｃｉｓ−シクロヘキシル置換ピリミジノン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100008866A1 (enExample) |
| EP (1) | EP2094704A4 (enExample) |
| JP (1) | JP2010509224A (enExample) |
| CN (1) | CN101558069A (enExample) |
| AU (1) | AU2007325940A1 (enExample) |
| CA (1) | CA2668579A1 (enExample) |
| WO (1) | WO2008066664A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007288203B2 (en) * | 2006-08-23 | 2013-01-17 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
| CN102329325B (zh) * | 2010-07-07 | 2013-11-27 | 中国科学院广州生物医药与健康研究院 | 吡咯并嘧啶酮类dpp-iv抑制剂 |
| CN102976970B (zh) * | 2012-12-05 | 2014-12-17 | 南京理工大学 | 一种异氰基化合物的制备方法 |
| CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| WO2016073738A2 (en) * | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371587A1 (en) * | 2002-01-17 | 2005-06-27 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
| AU2004290626A1 (en) * | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| GB0506147D0 (en) * | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006122200A1 (en) * | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
-
2007
- 2007-11-05 CA CA002668579A patent/CA2668579A1/en not_active Abandoned
- 2007-11-05 CN CNA2007800461311A patent/CN101558069A/zh active Pending
- 2007-11-05 AU AU2007325940A patent/AU2007325940A1/en not_active Abandoned
- 2007-11-05 JP JP2009535353A patent/JP2010509224A/ja active Pending
- 2007-11-05 EP EP07870847A patent/EP2094704A4/en not_active Withdrawn
- 2007-11-05 WO PCT/US2007/023318 patent/WO2008066664A2/en not_active Ceased
-
2009
- 2009-05-06 US US12/436,587 patent/US20100008866A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509224A5 (enExample) | ||
| JP2010502576A5 (enExample) | ||
| CA2671982C (en) | Methods of using mek inhibitors | |
| JP6461118B2 (ja) | ブロモドメイン阻害剤としての新規の置換された二環式化合物 | |
| CN103096718B (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| CN109381469A (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| JP2017526711A5 (enExample) | ||
| JP2010513283A (ja) | 新規なオキサジアゾール化合物 | |
| JP2008534486A5 (enExample) | ||
| CA2683641A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| JP2016512511A5 (enExample) | ||
| JP2018501315A5 (enExample) | ||
| JP2006520805A5 (enExample) | ||
| HRP20160036T1 (hr) | Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin | |
| CN104302626A (zh) | 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途 | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| HRP20100516T1 (hr) | Tiazolpirazolopirimidini kao antagonisti receptora crf1 | |
| JP7106528B2 (ja) | Ｔｒｐｖ４拮抗薬 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| HRP20171031T1 (hr) | Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| RU2018125277A (ru) | Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения | |
| HRP20161558T1 (hr) | Novi biciklički piridinoni | |
| JP2009515814A5 (enExample) |